1. 方法論と範囲
1.1. 調査方法
1.2. 調査目的と調査範囲
2. 定義と概要
3. エグゼクティブ・サマリー
3.1. 薬剤タイプ別スニペット
3.2. 用途別スニペット
3.3. 製品形態別スニペット
3.4. 投与経路別スニペット
3.5. 販売チャネル別スニペット
3.6. 地域別スニペット
4. ダイナミクス
4.1. 影響要因
4.1.1. 推進要因
4.1.1.1. 前立腺がんの有病率の上昇
4.1.1.2. 研究開発の増加
4.1.2. 阻害要因
4.1.2.1. 高い製造コスト
4.1.2.2. XX
4.1.3. 機会
4.1.4. 影響分析
5. 産業分析
5.1. ポーターのファイブフォース分析
5.2. サプライチェーン分析
5.3. 価格分析
5.4. 規制分析
5.5. 特許分析
5.6. PESTLE分析
5.7. SWOT分析
5.8. DMI意見
6. 医薬品タイプ別
6.1. はじめに
6.1.1. 薬物タイプ別市場規模分析および前年比成長率分析（%） 6.1.2.
6.1.2. 市場魅力度指数（薬物タイプ別
6.2. トリプトレリンパモエート*市場
6.2.1. 序論
6.2.2. 市場規模分析と前年比成長率分析(%)
6.3. トリプトレリン酢酸塩
6.4. トリプトレリンエンボネート
7. 用途別
7.1. はじめに
7.1.1. 市場規模分析および前年比成長率分析（%）, アプリケーション別
7.1.2. 市場魅力度指数：用途別
7.2. がん
7.2.1. 序論
7.2.2. 市場規模分析と前年比成長率分析(%)
7.3. 根治的前立腺切除術
7.4. 中枢性思春期早発症
7.5. 子宮内膜症
8. 製品形態別
8.1. 製品紹介
8.1.1. 市場規模分析および前年比成長率分析（%）, 製品形態別
8.1.2. 市場魅力度指数（製品形態別
8.2. 凍結乾燥粉末
8.2.1. はじめに
8.2.2. 市場規模分析と前年比成長率分析(%)
8.3. プレフィルドシリンジ
8.4. バイアル
9. 投与経路別
9.1. はじめに
9.1.1. 市場規模分析および前年比成長率分析（％）、投与経路別
9.2. 市場魅力度指数（投与経路別
9.3. 皮内*市場
9.3.1. はじめに
9.3.2. 市場規模分析と前年比成長率分析(%)
9.4. 筋肉内
9.5. 皮下
10. 流通チャネル別
10.1. はじめに
10.1.1. 市場規模分析および前年比成長率分析（%）, 流通チャネル別
10.1.2. 市場魅力度指数（流通チャネル別
10.2. 病院薬局
10.2.1. 序論
10.2.2. 市場規模分析と前年比成長率分析(%)
10.3. オンライン薬局
10.4. 小売薬局
11. 地域別
11.1. はじめに
11.1.1. 地域別市場規模分析および前年比成長率分析(%)
11.1.2. 市場魅力度指数、地域別
11.2. 北米
11.2.1. 序論
11.2.2. 主な地域別ダイナミクス
11.2.3. 薬剤タイプ別市場規模分析および前年比成長率分析（%） 11.2.4.
11.2.4. 市場規模分析およびYoY成長率分析（%）、用途別
11.2.5. 市場規模分析および前年比成長率分析（%）, 製品形態別
11.2.6. 市場規模分析および前年比成長率分析（%）, 投与経路別
11.2.7. 市場規模分析および前年比成長率分析（%）, 流通チャネル別
11.2.8. 市場規模分析および前年比成長率分析（%）, 国別
11.2.8.1. 米国
11.2.8.2. カナダ
11.2.8.3. メキシコ
11.3. ヨーロッパ
11.3.1. はじめに
11.3.2. 主な地域別動向
11.3.3. 薬剤タイプ別市場規模分析および前年比成長率分析（%） 11.3.4.
11.3.4. 市場規模分析およびYoY成長率分析（%）、用途別
11.3.5. 市場規模分析および前年比成長率分析（%）, 製品形態別
11.3.6. 市場規模分析および前年比成長率分析（%）, 投与経路別
11.3.7. 市場規模分析および前年比成長率分析（%）：流通チャネル別
11.3.8. 市場規模分析および前年比成長率分析（%）, 国別
11.3.8.1. ドイツ
11.3.8.2. イギリス
11.3.8.3. フランス
11.3.8.4. イタリア
11.3.8.5. スペイン
11.3.8.6. その他のヨーロッパ
11.4. 南米
11.4.1. はじめに
11.4.2. 地域別主要市場
11.4.3. 薬剤タイプ別市場規模分析および前年比成長率分析（%） 11.4.4.
11.4.4. 市場規模分析およびYoY成長率分析（%）、用途別
11.4.5. 市場規模分析および前年比成長率分析（%）, 製品形態別
11.4.6. 市場規模分析および前年比成長率分析（%）, 投与経路別
11.4.7. 市場規模分析および前年比成長率分析（%）：流通チャネル別
11.4.8. 市場規模分析および前年比成長率分析（%）, 国別
11.4.8.1. ブラジル
11.4.8.2. アルゼンチン
11.4.8.3. その他の南米諸国
11.5. アジア太平洋
11.5.1. はじめに
11.5.2. 主な地域別ダイナミクス
11.5.3. 薬剤タイプ別市場規模分析および前年比成長率分析（%） 11.5.4.
11.5.4. 市場規模分析および前年比成長率分析（%）：用途別
11.5.5. 市場規模分析および前年比成長率分析（%）, 製品形態別
11.5.6. 市場規模分析および前年比成長率分析（%）, 投与経路別
11.5.7. 市場規模分析および前年比成長率分析（%）：流通チャネル別
11.5.8. 市場規模分析および前年比成長率分析（%）, 国別
11.5.8.1. 中国
11.5.8.2. インド
11.5.8.3. 日本
11.5.8.4. 韓国
11.5.8.5. その他のアジア太平洋地域
11.6. 中東・アフリカ
11.6.1. 序論
11.6.2. 主な地域別ダイナミクス
11.6.3. 薬剤タイプ別市場規模分析および前年比成長率分析（%） 11.6.4.
11.6.4. 市場規模分析およびYoY成長率分析（%）、用途別
11.6.5. 市場規模分析および前年比成長率分析（%）, 製品形態別
11.6.6. 市場規模分析および前年比成長率分析（%）, 投与経路別
11.6.7. 市場規模分析および前年比成長率分析（%）：流通チャネル別
12. 競合情勢
12.1. 競争シナリオ
12.2. 市場ポジショニング／シェア分析
12.3. M&A分析
13. 企業プロフィール
13.1. Ipsen*
13.1.1. 会社概要
13.1.2. 製品ポートフォリオと説明
13.1.3. 財務概要
13.1.4. 主な展開
13.2. Ferring Pharmaceuticals Pvt Ltd
13.3. Chengdu Tiantaishan Pharmaceutical Co., Ltd
13.4. Tecnofarma
13.5. Debiopharm Group
13.6. Bachem
13.7. Actavis Specialty Pharmaceuticals Co
13.8. Arbor Pharmaceuticals, LLC
13.9. Dr. Reddy’s Laboratories Ltd
13.10. Teva Pharmaceutical Industries Ltd (*リストは除外)
14. 付録
14.1. 会社概要とサービス
14.2. お問い合わせ

Report Overview
Global Triptorelin Market reached US$ 9.5 billion in 2023 and is expected to reach US$ 18.3 billion by 2031, growing at a CAGR of 4.7% during the forecast period 2024-2031.

Triptorelin is a decapeptide analogue of gonadotropin releasing hormone (GnRH) that stimulates the synthesis and release of luteinizing hormone (LH) and follicle stimulating hormone (FSH), which stimulate testosterone production in the male testes and estrogen production in the female ovaries. It and other GnRH agonists initially increase gonadotropin release, but down-regulate their synthesis, resulting in a decline in testosterone and estrogen production. Triptorelin, alone or combined with other antiandrogens, has been found to be palliative in advanced prostate cancer and as effective as surgical castration.

Market Dynamics: Drivers & Restraints
Rise in the prevalence of prostrate cancer
The triptorelin market is expected to grow due to the increasing prevalence of prostate cancer worldwide and its widespread use in prostate cancer treatment to reduce testosterone production. n men with locally advanced or metastatic prostate cancer, administration of triptorelin leads to subjective improvement in lower urinary tract symptoms and pain, as well as objective responses such as decreased serum levels of acid and alkaline phosphatase and prostate-specific antigen, decreased prostate volume, and regression of skeletal metastases.For instance, according to the American Cancer Society predicts 299,010 new prostate cancer cases and 35,250 deaths have been occurred in the United States for 2024.

High manufacturng costs
The triptorelin drug market faces significant challenges due to high manufacturing costs, which are passed down to consumers as high medical costs. The unique nature of the drug's raw materials necessitates high-quality production. Additionally, the intricacy of the triptorelin manufacturing process, which involves biological or chemical procedures, limits product availability to those who can afford it.

Market Segment Analysis
The global triptorelin market is segmented based on drug type, application, product form, route of adminstration, distribution channel and region.
The triptorelin pamoate from the drug type segment accounted for approximately 45.3% of the Triptorelin market share
The triptorelin pamoate from the drug type segment accounted for approximately 45.3%. Triptorelin Pamoate is the pamoate salt of triptorelin, a synthetic decapeptide agonist analog of luteinizing hormone releasing hormone (LHRH). Possessing greater potency than endogenous LHRH, triptorelin reversibly represses gonadotropin secretion after prolonged administration. After chronic, continuous administration, a sustained decrease in LH, FSH and testicular and ovarian steroidogenesis is observed. The serum testosterone concentration may fall to levels typically seen in surgically castrated men. (NCI04).

Market Geographical Share
North America is estimated to hold about 41.04% of the total market share throughout the forecast period
North America is estimated to hold about 41.04% of the total market share throughout the forecast period due to the increasing prevalence of hormone-dependent cancers like prostate and breast cancer in the region, the need for advanced therapies like Triptorelin, the region's well-established healthcare infrastructure, high healthcare spending, the presence of key pharmaceutical companies, and ongoing research in hormonal therapies. The aging population in North America, more susceptible to hormone-related conditions, further boosts the demand for Triptorelin, as it is a treatment option for these cancers.
For instance, in the year 2022, Arbor Pharmaceuticals, LLC, subsidiary of Azurity Pharmaceuticals, Inc. is currently offering reimbursement for the patients undergoing treatment for central precocious puberty (CPP) with Triptodur (triptorelin). The company is providing the drug at a low cost so that all the patients can afford the drug.
Under this reimbursement policy, the patient can save almost IJS$ 10,000 per year. The offer is valid in the U.S. and Puerto Rico as allowed by law. Under the policy, only those patients areeligible for the reimbursement policy, who are insured in whole or in part, by Medicaid, Medicare, or other federal or state healthcare programs.

Market Segmentation
By Drug Type
Triptorelin Pamoate
Triptorelin Acetate
Triptorelin Embonate
By Application
Cancer
Radical Prostatectomy
Central Precocious Puberty
Endometriosis
By Product Form
Lyophilized Powder
Pre-Filled Syringes
Vials
By Route of Administration
Intradermal
Intramuscular
Subcutaneous
By Distribution Channel
Hospital Pharmacies
Online Pharmacies
Retail Pharmacies
By Region
North America
U.S.
Canada
Mexico
Europe
Germany
UK
France
Italy
Spain
Rest of Europe
South America
Brazil
Argentina
Rest of South America
Asia-Pacific
China
India
Japan
South Korea
Rest of Asia-Pacific
Middle East and Africa

Market Competitive Landscape
The major global players in the market include Ipsen, Ferring Pharmaceuticals Pvt Ltd, Chengdu Tiantaishan Pharmaceutical Co., Ltd, Tecnofarma, Debiopharm Group, Bachem, Actavis Specialty Pharmaceuticals Co, Arbor Pharmaceuticals, LLC, Dr. Reddy's Laboratories Ltd, Teva Pharmaceutical Industries Ltd among others.

Key Developments
In February 2022, Debiopharm, a Swiss biopharmaceutical company and Aspen, a South African headquartered multinational pharmaceutical company announced their partnership to launch Trelstar (Triptorelin) in South Africa for the treatment of locally advanced and metastatic hormone dependent prostate cancer. (Trelstar, a synthetic analogue of GnRH (Gonadotropin Releasing Hormone) developed by Debiopharm, will be marketed by Aspen in South Africa.

Why Purchase the Report?
To visualize the global triptorelin
Market Segmentation based on drug type, application, product form, route of administration, distribution channel and region as well as understand key commercial assets and players.
Identify commercial opportunities by analyzing trends and co-development.
Excel data sheet with numerous data points of the triptorelin market level with all segments.
PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
Product mapping available as excel consisting of key products of all the major players.
The global Triptorelin market report would provide approximately 64 tables, 61 figures and 186 pages.

Target Audience 2024
Manufacturers/ Buyers
Industry Investors/Investment Bankers
Research Professionals
Emerging Companies

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Drug Type
3.2. Snippet by Application
3.3. Snippet by Product Form
3.4. Snippet by Route of Administration
3.5. Snippet by Distribution Channel
3.6. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Rise in the prevalence of prostate cancer
4.1.1.2. Rise in the research and development
4.1.2. Restraints
4.1.2.1. High manufacturing costs
4.1.2.2. XX
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. Patent Analysis
5.6. PESTLE Analysis
5.7. SWOT Analysis
5.8. DMI Opinion
6. By Drug Type
6.1. Introduction
6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
6.1.2. Market Attractiveness Index, By Drug Type
6.2. Triptorelin Pamoate*
6.2.1. Introduction
6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Triptorelin Acetate
6.4. Triptorelin Embonate
7. By Application
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
7.1.2. Market Attractiveness Index, By Application
7.2. Cancer*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Radical Prostatectomy
7.4. Central Precocious Puberty
7.5. Endometriosis
8. By Product Form
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Form
8.1.2. Market Attractiveness Index, By Product Form
8.2. Lyophilized Powder*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Pre-Filled Syringes
8.4. Vials
9. By Route of Administration
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
9.2. Market Attractiveness Index, By Route of Administration
9.3. Intradermal*
9.3.1. Introduction
9.3.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.4. Intramuscular
9.5. Subcutaneous
10. By Distribution Channel
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.1.2. Market Attractiveness Index, By Distribution Channel
10.2. Hospital Pharmacies*
10.2.1. Introduction
10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Online Pharmacies
10.4. Retail Pharmacies
11. By Region
11.1. Introduction
11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
11.1.2. Market Attractiveness Index, By Region
11.2. North America
11.2.1. Introduction
11.2.2. Key Region-Specific Dynamics
11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Form
11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11.2.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.2.8.1. U.S.
11.2.8.2. Canada
11.2.8.3. Mexico
11.3. Europe
11.3.1. Introduction
11.3.2. Key Region-Specific Dynamics
11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Form
11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11.3.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.3.8.1. Germany
11.3.8.2. UK
11.3.8.3. France
11.3.8.4. Italy
11.3.8.5. Spain
11.3.8.6. Rest of Europe
11.4. South America
11.4.1. Introduction
11.4.2. Key Region-Specific Dynamics
11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Form
11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11.4.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.4.8.1. Brazil
11.4.8.2. Argentina
11.4.8.3. Rest of South America
11.5. Asia-Pacific
11.5.1. Introduction
11.5.2. Key Region-Specific Dynamics
11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Form
11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11.5.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.5.8.1. China
11.5.8.2. India
11.5.8.3. Japan
11.5.8.4. South Korea
11.5.8.5. Rest of Asia-Pacific
11.6. Middle East and Africa
11.6.1. Introduction
11.6.2. Key Region-Specific Dynamics
11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Form
11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
11.6.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
12. Competitive Landscape
12.1. Competitive Scenario
12.2. Market Positioning/Share Analysis
12.3. Mergers and Acquisitions Analysis
13. Company Profiles
13.1. Ipsen*
13.1.1. Company Overview
13.1.2. Product Portfolio and Description
13.1.3. Financial Overview
13.1.4. Key Developments
13.2. Ferring Pharmaceuticals Pvt Ltd
13.3. Chengdu Tiantaishan Pharmaceutical Co., Ltd
13.4. Tecnofarma
13.5. Debiopharm Group
13.6. Bachem
13.7. Actavis Specialty Pharmaceuticals Co
13.8. Arbor Pharmaceuticals, LLC
13.9. Dr. Reddy's Laboratories Ltd
13.10. Teva Pharmaceutical Industries Ltd (*LIST NOT EXHAUSTIVE)
14. Appendix
14.1. About Us and Services
14.2. Contact Us

❖ 世界のトリプトレリン市場に関するよくある質問(FAQ) ❖

・トリプトレリンの世界市場規模は？
→DataM Intelligence社は2023年のトリプトレリンの世界市場規模を95億米ドルと推定しています。

・トリプトレリンの世界市場予測は？
→DataM Intelligence社は2031年のトリプトレリンの世界市場規模を183億米ドルと予測しています。

・トリプトレリン市場の成長率は？
→DataM Intelligence社はトリプトレリンの世界市場が2024年～2031年に年平均4.7%成長すると予測しています。

・世界のトリプトレリン市場における主要企業は？
→DataM Intelligence社は「Ipsen、Ferring Pharmaceuticals Pvt Ltd、Chengdu Tiantaishan Pharmaceutical Co., Ltd、Tecnofarma、Debiopharm Group、Bachem、Actavis Specialty Pharmaceuticals Co.、Arbor Pharmaceuticals, LLC、Dr. Reddy's Laboratories Ltd、Teva Pharmaceutical Industries Ltdなど ...」をグローバルトリプトレリン市場の主要企業として認識しています。

※上記FAQの市場規模、市場予測、成長率、主要企業に関する情報は本レポートの概要を作成した時点での情報であり、納品レポートの情報と少し異なる場合があります。